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ABSTRACT
Background
Proteasome inhibition represents a promising novel anticancer therapy, and bortezomib is a
highly selective reversible inhibitor of the proteasome complex. Acute myeloid leukemia (AML)
is an immnunophenotypically heterogeneous group of diseases, with CD34+ cases being asso-
ciated with drug resistance and poor outcome. We investigated the effects of bortezomib on the
growth and survival of AML cells.
Design and Methods
We studied the in vitro activity and mechanism of action of bortezomib on both cell lines and
fresh cells from 28 AML patients including CD34+ and CD34– cases.
Results
Bortezomib showed potent anti-AML activity (IC50 < 50 nM), which was greater than that of con-
ventional agents (doxorubicin, cytarabine and fludarabine). Moreover, synergistic effects were
observed when bortezomib was adminstered in combination with doxorubicin and cytarabine.
Mechanistically, bortezomib induced accumulation of cells in the G2/M phase, with up-regula-
tion of p27, together with cell death through an increase in the mitochondrial outer membrane
permeability involving caspase-dependent and -independent pathways. The apoptotic activity
of bortezomib on fresh CD34+ blast cells from patients was similar to that observed on CD34–
blast cells. Importantly, bortezomib was significantly more active than doxorubicin in the imma-
ture CD34+ cells, while there were no differences in its action on CD34– cells.
Conclusions
Bortezomib induces apoptosis in acute myeloid leukemia cells in vitro. Whether this drug might
be useful in the treatment of patients with acute myeloid leukemia can be established only in
ad hoc clinical trials.
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Introduction
The ubiquitin–proteasome pathway plays a funda-
mental role in cellular homeostasis as a critical regulator
of cell proliferation and apoptosis. For this reason, the
proteasome represents an attractive target for therapeu-
tic intervention in cancer patients,1 and this is supported
by the results obtained in different malignancies with
the proteasome inhibitor bortezomib (Velcade®, former-
ly PS-341), which is a highly selective, reversible
inhibitor of the 26S subunit of the proteasome complex.2
Studies on the mechanism of action of bortezomib have
indicated that this drug stabilizes p21, p27 and p53, as
well as the pro-apoptotic Bid and Bax proteins, caveolin-
1 and IkB-a.3,4 The last protein prevents activation of
NFkB-induced cell survival pathways in several cellular
systems, including a multiple myeloma model.5 The
anticancer effects of bortezomib have been demonstrat-
ed in vitro and in vivo for different malignancies such as
multiple myeloma,6,7 adult T-cell leukemia,8 melanoma,9
lung,10,11 breast,12 pancreatic,13,14 prostate,15,16 ovarian,17
head and neck,18 and colon cancer.19 Moreover, several in
vitro experiments have also shown that bortezomib
enhances the antitumor properties of various antineo-
plastic drugs.20-25
Clinical investigations concerning the efficacy and
safety of bortezomib alone or in combination with
chemotherapy in multiple myeloma have been complet-
ed26,27 and bortezomib was approved in 2003 for the
treatment of relapsed and refractory multiple myelo-
ma.28 More recently, bortezomib was also approved for
the treatment of mantle cell lymphoma. As far as con-
cerns acute myeloid leukemia (AML), three small clinical
trials have been conducted;29-31 in two of them, borte-
zomib was combined with conventional agents,30,31 and
in one it was used as a single agent, but only modest and
transient antileukemic activity was observed.29
In spite of these data, there is little information on the
in vitro activity and mechanism of action of bortezomib
in AML to support its clinical use. This is important, par-
ticularly due to the heterogeneity of AML, including a
wide array of genetic lesions and immunophenotypic
profiles. The CD34 antigen identifies early progenitor
cells and, accordingly, AML can be divided into imma-
ture and mature forms (CD34+ and CD34–, respectively),
the former subset associated with drug resistance and
poorer outcome,32-35 as compared to the more mature
CD34– cases. Moreover, at relapse, blast cells usually dis-
play a more immature phenotype, as a reflection of drug
resistance.36,37 In fact, it has been suggested that the pres-
ence of an immature phenotype,32,35 together with age
and cytogenetics represent important prognostic factors
in AML.38 On this background, we carried out a detailed
analysis of the in vitro activity and mechanism of action
of bortezomib on AML cells using both cell lines and
fresh cells from patients including CD34+ and CD34–
cases. In addition, we compared the activity of borte-
zomib with that of conventional agents used for the
treatment of AML. 
Design and Methods
Reagents and immunochemicals
Cell culture media, serum and penicillin-streptomycin
were purchased from Invitrogen Corporation (Gaithers-
burg, MD, USA). Bortezomib (formerly known as PS-
341; Millenium Pharmaceutics Inc. Cambridge, MA,
USA) was dissolved in DMSO and stored at –20ºC until
use. Doxorubicin, cytarabine (ara-C) and fludarabine
were purchased from Sigma (USA). Annexin V-FITC
was obtained from Becton Dickinson (San Diego, CA,
USA). Calpeptin and Z-VAD-FMK were from Cal-
biochem (San Diego, CA, USA). Other generic chemicals
were purchased from Sigma Chemical Co., Roche
Biochemicals (Mannheim, Germany), or Merck
(Darmstadt, Germany). The origins of the different
monoclonal antibodies employed in the western blot-
ting analyses were as follows: the anti-p21, anti-pErk,
anti-Erk1/2, and anti-caspase-3, were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); anti-Apaf-1, anti-
caspase-8, anti-caspase-9, anti-AIF, anti-Bcl-X, anti-
PARP, anti-Bcl-2, anti-Cdk4 and anti-cyclin D1 antibod-
ies were from Becton Dickinson, anti-p53 antibody was
from Calbiochem Science, and the HRP-conjugated sec-
ondary antibodies were from Bio-Rad.
Cell lines: cell proliferation, cell cycle and apoptosis
assays
All AML cell lines (HEL, KG-1, MV4-11 and HL-60)
were cultured in RPMI 1640 containing 10% fetal-
bovine serum (Gibco), 2x10-3 M glutamine, 100 units/mL
penicillin and 100 ∝g/mL streptomycin at 37°C in a
humidified atmosphere in the presence of 5% CO2-95%
air. HL60 cells were derived from a patient with FAB M2
AML, the HEL and KG-1 cell lines were derived from
patients with erythroid leukemia (FAB M6), while the
source of MV4-11 was a patient with myelomonocytic
leukemia (FAB M4). The proliferation of AML cells was
examined using MTT colorimetric assays as described
elsewhere.39,40 Pilot studies were conducted on all the
AML cell lines to optimize cell concentrations and incu-
bation times with the different drugs. Interactions
between bortezomib and other anti-AML drugs were
analyzed using the Calcusyn software program (Biosoft,
Ferguson, MO, USA). Data from cell viability assays
(MTT) are expressed as a fraction of cells with growth
affected (FA) in drug-treated versus untreated cells. This
program is based upon the Chou and Talalay method.41,42
For flow cytometric evaluation of apoptosis, 1106 of
HEL cells were washed with phosphate-buffered saline
(PBS) and resuspended in binding buffer (10 mM
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Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2).
Cells were incubated with 5 mL of annexin-V-FITC for
15 min at room temperature in the dark, and then 10 mL
of propidium iodide (PI) were added.
To obtain a quantitative evaluation of the mitochondr-
ial transmembrane potential (Ψm), cells were incubated
in PBS with 20 nM 3,3´-dihexyloxacarbocyanine iodide
[DiOC6(3)] (Molecular Probes, Leiden, The Netherlands)
for 20 min at 37ºC in the dark, washed with PBS and,
then, following addition of 10 mL PI (Calbiochem, San
Diego, CA, USA) underwent flow activated cell sorting
(FACS) on a FACScalibur flow cytometer (BD Bio-
sciences) and analysis with the Paint-a-gate program.
To analyze the cell cycle distribution, cells were made
permeable by the addition of 70% ethanol for 4 h at 4ºC
and stained with PI in the presence of 5 mg/mL RNAse
(Sigma). Ten thousand events were acquired on a
FACScalibur flow cytometer (BD Biosciences) and ana-
lyzed with the Paint-a-Gate program.
Western blotting
Cell lines were treated with 50 nM of Bortezomib and
were collected and centrifuged at 10,000 × g for 2 min.
The cells were then washed with PBS and lysed in ice-
cold lysis buffer (140 mM NaCl, 10 mM EDTA, 10%
glycerol, 1% Nonidet P-40, 20 mM Tris (pH 7.0), 1 mM
pepstatin, 1 mg/mL aprotinin, 1 mg/mL leupeptin, 1 mM
sodium orthovanadate). Samples were centrifuged at
10,000 × g at 4ºC for 10 min and supernatants were
transferred to new tubes. 
Subcellular fractionation
HEL cells were harvested in isotonic mitochondrial
buffer (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5
mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1
mM pepstatin, 1 mg/mL aprotinin, 1 mg/mL leupeptin, 1
mM sodium orthovanadate) and Dounce homogenized
by 60-70 strokes. Samples were transferred to Eppendorf
tubes and centrifuged at 770 × g for 10 min at 4ºC to sep-
arate nuclei and unbroken cells. The resulting super-
natant was centrifuged at 10,000 × g for 25 min at 4ºC to
obtain the mitochondrial pellet. The supernatant was
further centrifuged at 100,000 × g for 1 hour at 4ºC to
yield the final soluble cytosolic fraction.
Patients’ samples and apoptosis assays
For cytometric analyses of apoptosis in bone marrow
(BM), cell subpopulations from 29 AML patients, exclud-
ing those with acute promyelocytic leukemia, were
obtained at diagnosis before any treatment. Both CD34+
and CD34– cells co-existed in nine cases. In seven cases, all
blast cells were CD34+, while in the other 13 samples, they
were all CD34–. Accordingly, a total of 16 samples had a
significant CD34+ population, either as a pure population
or in a mixture, and in 22 samples a CD34– population was
identified and available for investigation of drug-induced
antitumor activity. The multiparametric flow cytometry
analysis of the CD34– populations showed that in all cases,
these populations were inmunophenotypically more
mature cells based on the expression of different matura-
tion antigens (CD15, CD11b, CD64, CD14, CD65, cMPO,
CD45++). The average age of the patients was 64±12 years
(mean±SD). Cytogenetic information was available for 22
samples (7 complex karyotype or 11q23; 15 normal risk
karyotypes), the remaining seven patients had no mitoses.
According to the FAB classification, the distribution of
cases was as follows: two M0, (7%); eight M1, (28%); five
M2, (17%); four M4, (14%); eight M5 (28%); one M6,
(4%) and one case was considered not classifiable. Patients
were treated according to the Spanish Cooperative
PETHEMA group’s protocols LAM99 <65 (n=19), and
LAM99>65 (n=1), and 68% (n=14) of 20 evaluable patients
achieved morphological complete remission. The remain-
ing patients (n=9) were considered to have received only
supportive care, due to older age. 
Mononuclear cells (MNC) were isolated by a Ficoll-
Hipaque density sedimentation and maintained in IMDM
containing 15% FCS; the percentage of blasts after purifi-
cation was 88±9%. To consider a MNC sample as valid,
it had to have less that 5% trypan blue-positive cells at
arrival at our laboratory, and, after incubation for 18 h
with drugs, there had to be less than 40% annexin V pos-
itive events in the control. In order to analyze the apop-
totic activity of bortezomib and to compare it with that
of doxorubicin and cytarabine, 1×106 BM cells were incu-
bated in six-well plates with bortezomib (50 nM), dox-
orubicin (1 mM) or cytarabine (1 mM), or without any
drug (control) for 18 h at 37 ºC in a humidified atmos-
phere in the presence of 5% CO2-95% air. The drug con-
centrations were selected based on the median plasma
levels achieved in patients for these drugs and our results
in cell lines. Subsequently, cells were incubated for 15 min
at room temperature in the dark with 5 mL annexin-V-
FITC (Bender MedSystems, Burlingame, CA, USA)
together with a combination of monoclonal antibodies:
anti-CD33-PE, anti-CD34-PerCP, anti-CD45-APC (BD
Biosciences). A total of 50,000 cells were acquired on a
FACScalibur flow cytometer (BD Biosciences) and ana-
lyzed with the Paint-a-Gate program. Using quadruple
staining (annexin V/CD33/CD34/CD45), we were able to
identify and distinguish the most immature blast cell pop-
ulation (CD34+, CD45dim) from the more mature blast cell
population (CD33+, CD34–) and normal residual lympho-
cytes (CD45+, SSClo). The number of apoptotic cells was
measured in each cell population. The percentage of
apoptotic events was corrected according to the propor-
tion of apoptotic cells in the control tube (to which no
drug was added). 
Statistical analysis
The percentage of apoptotic cells referred to the viable
fraction of cells, which was calculated using the control
tube, for normalization in order to reduce the variability
among samples. Induction of apoptosis (annexin V+
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events) was calculated on the total blast cell population,
CD34+ blast cells, CD34– blast cells and normal residual
lymphocytes. Statistical analyses were performed using
the SPSS 11.0 statistical package.
Results
Activity of bortezomib in AML cell lines
To investigate the effect of bortezomib on the growth
and survival of AML cells, we first used MTT assays on
four different representative AML cell lines. Treatment
with increasing doses of bortezomib (0.1-100 nM) for 48
hours potently suppressed MTT uptake (Figure 1A), with
IC50 values between 5 nM and 10 nM for all four cell lines
used. Comparisons of the IC50 values of bortezomib with
those of other drugs commonly used in AML indicated
that bortezomib was clearly more potent than doxoru-
bicin (Figure 1B), cytarabine (Figure 1C) and fludarabine
(Figure1D). MV4-11 was resistant to doxorubicin, and
the IC50 value for doxorubicin for HEL, HL60 and KG-1
were 500 nM, 1 mM and 1 mM, respectively. All cell lines
were resistant to pharmacological doses of cytarabine,
and cell growth inhibition was only observed with
micromolar concentrations. MV4-11 was resistant to flu-
darabine and growth inhibition appeared only at 10 mM,
while the IC50 values for HEL and KG-1 were 500 nM,
and that for the HL60 cell line, 3 mM.
Bortezomib increases the action of doxorubicin 
and cytarabine
In order to investigate whether bortezomib could
increase the activity of conventional drugs used in AML
treatment, HEL cells were treated with several combina-
tions of bortezomib and conventional drugs (doxoru-
bicin, fludarabine and cytarabine). For these experi-
ments, we used suboptimal doses of the compounds,
and evaluated their combined effect by MTT
absorbance assays, then analyzed the data using the
Calcusyn program. As shown in Figure 1E, bortezomib
was found to synergistically increase the anti-AML
effect of doxorubicin (CI: 0.17) and cytarabine (CI: 0.51).
However, bortezomib did not enhance the ability of flu-
darabine to inhibit the proliferation of HEL cells.
Figure 1. Effect of bortezomib
on the proliferation of acute
myeloid leukemia cells. MTT
uptakes of acute myeloid
leukemia cell lines incubated
with different doses of borte-
zomib (A), doxorubicin (B),
cytarabine (C), and fludarabine
(D). Cells were plated at identi-
cal densities in 96-well dishes.
Bortezomib, doxorubicin,
cytarabine and fludarabine
were added at the indicated
concentrations. MTT uptake
assays were performed 48
hours later as described in the
Design and Methods section.
The average proliferation val-
ues of control untreated sam-
ples were taken as 100%.
Data are represented as the
mean ± SD of quadruplicates
of an experiment that was
repeated at least twice. (E)
Bortezomib (15 nM) was com-
bined with doxorubicin (250
nM), cytarabine (250 nM) or
fludarabine (250 nM) and 48
hours later, MTT assays were
done in HEL cells.
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Bortezomib provokes cell cycle arrest in AML cells
We next evaluated whether the reduced MTT uptake
observed in AML cell lines treated with bortezomib was
due to stimulation of cell death or cell cycle arrest. HEL
cells were cultured with bortezomib 50 nM for 0, 3, 6,
12, 18 and 24 hours and then cell cycle profile was ana-
lyzed by PI staining. As shown in Figure 2A, bortezomib
caused an increase in G2/M and a marked decrease in
G0/G1 and S phases in a time-dependent manner.
Analyses of several proteins implicated in cell cycle pro-
gression indicated that bortezomib decreased the levels
of pRb, but rapidly increased the levels of p27 and cyclin
E. Bortezomib also decreased the amount of IkB, and
provoked a shift in the molecular weight towards a
faster migrating form, likely representing dephosphory-
lated or underphosphorylated IkB. No major changes in
p21, cyclin B, CDK2, CDK4, NFkB or p53 levels were
observed, except at longer incubation times after which
a decrease in most of these proteins was detected, prob-
ably due to massive protein degradation. 
Bortezomib causes apoptosis in AML cells
We then investigated whether bortezomib caused
apoptotic cell death. A significant, time-dependent
induction of annexin V-positive cells was observed in
HEL-cells after treatment with bortezomib (Figure 3A).
Treatment with bortezomib also caused internucleoso-
mal DNA fragmentation indicative of cell death (Figure
3B). As mitochondria appear to be organelles critically
involved in the triggering of apoptotic cell death, we
explored whether bortezomib altered mitochondrial
membrane potential (Ψm). Analysis of Ψm by the use of
the mitochondrial membrane potential probe DioC6(3)
showed a decrease in Ψm in cells treated with borte-
zomib, suggesting that mitochondria were indeed affect-
ed in HEL cells treated with this compound (Figure 3C).
We next evaluated the biochemical parameters that are
affected upon apoptotic cell death. Apoptosis triggered
by bortezomib provoked cleavage of PARP, caspase-3,
caspase-8 and caspase-9, with the generation of active
low Mr cleaved fragments, (Figure 4A), suggesting that
bortezomib exerts its effect by activating both the intrin-
sic and extrinsic caspase pathways. To investigate the
importance of caspases in the anti-leukemic action of
bortezomib, the ability of the caspase-3 inhibitor Z-
VAD-FMK to rescue from cells from bortezomib-induced
death was evaluated. HEL cells were preincubated for 60
minutes with Z-VAD-FMK, then bortezomib was added,
and the incubation continued for 24 hours. As shown in
Figure 4B, preincubation with the caspase-3 inhibitor
blocked bortezomib-induced cell death. These results
indicate that bortezomib activated the caspase-depend-
ent apoptotic pathway, and that this activation was the
main executor of cell death caused by this compound in
Figure 2. Bortezomib provokes G2/M cell cycle arrest. (A)
HEL cells were incubated with bortezomib (50 nM) for 3,
6, 12, 18 and 24 hours, and examined for cell cycle pro-
files using propidium iodide staining. The table shows the
percentages of cells in the different phases of the cell
cycle. (B) HEL cells were treated with bortezomib (50 nM)
for the indicated times, and the expression of cell cycle-
related proteins was analyzed by western blotting. The
position of the Mr marker is shown at the right.
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HEL cells. Loss of Ψm often reflects increases in mito-
chondrial outer membrane permeability. Bcl-2 family
members act as important regulators of mitochondrial
outer membrane permeability. Western blot analyses
indicated that bortezomib down-regulated the Bcl-2 fam-
ily member BCLX, but not BCL2, and slightly increased
MCL1 levels within the first 12 hours of treatment.
(Figure 4C). The increase in mitochondrial outer mem-
brane permeability also favors the release of AIF, a medi-
ator of caspase-independent cell death.43 Subcellular frac-
tionation of HEL cells treated for 18 hours with borte-
zomib showed that this drug caused a translocation of
AIF from the mitochondrial to the cytosolic fraction after
18 hours of treatment (Figure 4D).
Bortezomib induces apoptosis in CD34+ and CD34–
cell populations from fresh AML samples
We used a multiparametric flow cytometry method to
discriminate blast cells from normal residual lympho-
cytes, and, more interestingly, to discriminate between
immature and more mature leukemic cell populations.
The average percentage of apoptosis induced by borte-
zomib in the total blast cell of the whole series of 28
patients was 48±22% (mean±SD). In 14 samples, borte-
zomib induced apoptosis in ≥50% of leukemic cells. In
12 samples, between 50 and 20% of leukemic cells
became apoptotic, and only in two samples was the
level of apoptotic leukemic cells less than 20%. The
apoptotic activity of bortezomib on CD34+ blast cells
was similar to that observed in CD34– blast cells
(48±22% versus 57±27%, p=0.86; Figure 5A)
Bortezomib induces apoptosis more efficiently than
doxorubicin and cytarabine in AML samples from
patients
In a set of seven samples from AML patients, cytara-
bine (mean apoptosis induction±SD: 10±6%) was
shown to be less cytotoxic than either bortezomib or
doxorubicin (37±16% and 21±14%, respectively). For
this reason, we decided to continue our experiments
using only doxorubicin as the reference drug. When the
effect of bortezomib was compared with that induced
by doxorubicin, using both drugs at their optimal con-
Figure 3. Bortezomib causes apoptotic cell death in an acute
myeloid leukemia cell line. (A) Time-course of the effect of borte-
zomib on HEL cells. Cells were plated in 6-well plates, treated with
bortezomib (10 nM), and 18 hours later, stained with annexin V-
FITC and propidium iodide. (B) Bortezomib provokes internucleo-
somal DNA fragmentation, HEL cells were treated with bortezomib
for the indicated times and DNA was isolated and analyzed by
agarose gel electrophoresis. The position of the Mr markers is
shown at the right. (C) Bortezomib induces DΨm disruption. HEL
cells were treated with bortezomib (50 nM), and the DΨm analy-
ses performed with [DiOC6(3)] by flow cytometry. 
A
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B
Figure 4. Effect of bortezomib on apoptotic
pathways. (A) HEL cells were treated with
bortezomib (50 nM) for the indicated times,
and the expression of PARP, caspase-3, cas-
pase-8 and caspase-9 proteins analyzed by
western blotting. GAPDH was used as the
loading control. (B) Effect of the pan-caspase
inhibitor, Z-VAD-FMK, on bortezomib-induced
cell death. HEL cells were plated and pre-treat-
ed, where indicated, with Z-VAD-FMK (20 mM)
for 60 minutes. Bortezomib (50 nM) was
added to the corresponding samples, and the
experiment continued for 24 hours. MTT
absorbance tests were carried out as
described above. (C) The action of bortezomib
on the levels of Bcl-2, Bcl-X and MCL-1 pro-
teins. HEL cells were treated with bortezomib
(50 nM) for the indicated times, and cell
extracts were used for western blotting with
anti-Bcl-2, anti- Bcl-X or anti-MCL-1 antibodies.
(D) HEL cells were treated for the indicated
times with bortezomib (50 nM), and the sub-
cellular distribution of AIF in mitochondrial
and cytosolic fractions was analyzed by west-
ern blotting.
C
D
A B
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centrations, we observed that doxorubicin was slightly
less cytotoxic on the total blast cell population (39±33%
versus 48±22%, p=0.30 data not shown). More interesting
was the difference between the two compounds’ activi-
ties on CD34+ and CD34– blast cell subsets. Bortezomib
was significantly more active than doxorubicin in the
immature CD34+ cells (48±22% versus 31±26%,
p=0.002). (Figure 5A) In contrast, the activity of the two
drugs on the CD34– subset did not differ significantly
(57±27% versus 47±35%, p=0.17). Considering paired
samples from single cases, we observed that the effect of
bortezomib on CD34+ cells was greater than that of dox-
orubicin, suggesting that bortezomib may overcome
drug resistance associated with the immature phenotype
(Figure 5B). 
Bortezomib is less toxic than doxorubicin to normal
residual lymphocytes
Within the same samples we analyzed the toxicity to
residual normal lymphocytes. Our results demonstrate
that bortezomib is highly specific for leukemic cells,
since the toxicity to residual normal lymphocytes was
low (18±12%). Moreover, this toxicity was lower than
that observed for doxorubicin (Figure 5C). Finally, we
analyzed the toxicity of bortezomib against normal
CD34+ cells from four normal bone marrow samples,
and found that bortezomib is highly specific for CD34
leukemic cells, since toxicity to normal CD34+ cells was
low (5±5.2%, data not shown).
Discussion
Nearly 80% of patients with AML achieve a com-
plete remission with induction chemotherapy.
However, a high proportion relapse, and eventually die
of their disease.44,45 Recent studies have shown that pro-
teasome inhibitors represent a valuable novel anti-
cancer therapy. These agents inhibit the degradation of
multiubiquitinated target proteins, i.e., cell cycle regu-
Figure 5. Bortezomib has antileukemic activity against both CD34+ and CD34– AML cells. (A)
Bortezomib is more efficient than doxorubicin in CD34+ blast cells. Patients’ AML cells were
plated in 6-well plates, and treated with bortezomib (50 nM) or doxorubicin (1 mM). 18 hours
later, cells were stained with annexin V-FITC, and three monoclonal antibodies for leukemic-
associated antigens (CD33-PE, CD34–PerCP, and CD45-APC), CD34+ and CD34– blast cells
were discriminated, and the number of annexin V positive events were measured in all cellu-
lar populations in the sample and normalized to the viable cell fraction in the control, untreat-
ed cells, as described in the Design and Methods section. The apoptotic activity of bortezomib
on CD34+ blast cells was similar to that observed in CD34– blast cells (48±22% versus
57±27%, p= 0.86), while doxorubicin was more effective on CD34– cells, although differences
were not statistically significant (33,8±26% versus 51.4±35%, p= 0.75) Results are shown
as mean±SD and statistical analyses were performed by paired samples Wilcoxon’s rank test.
p values are indicated. (B) The comparative effect of apoptosis induced by bortezomib (50
nM) and doxorubicin (1 mM) on CD34+ blast cells of paired samples from single patients. The
percentage of apoptotic CD34+ blast cells is higher for bortezomib-treated cells than for dox-
orubicin-treated cells (mean±SD: 48±22% versus 31±26%, p=0.002). (C) Bortezomib is less
toxic to normal residual lymphocytes. In 22 samples normal residual lymphocytes were iden-
tified and the percentage of apoptotic events induced by either bortezomib or doxorubicin
was measured (18±12% versus 27±22%, p=0.053).
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latory proteins such as cyclins and cyclin-dependent
kinase inhibitors, and regulate cell cycle progression.46
Bortezomib is the first proteasome inhibitor that has
been introduced into clinical practice for the treatment
of relapsed multiple myeloma,2,28,47,48 and active clinical
investigation is ongoing in other malignancies.49-55 In
this study we provide the framework for more inten-
sive clinical investigation of bortezomib in AML. MTT
uptake experiments on AML cell lines, sensitive and
resistant to conventional chemotherapeutic agents,
indicate that bortezomib is efficient at concentrations
in the low nanomolar range, within pharmacologically
achievable doses. Moreover, the in vitro activity of
bortezomib appears to be clearly superior to that of
conventional agents currently used for AML treatment
such as doxorubicin, cytarabine and fludarabine. In
addition, bortezomib showed a synergistic effect with
doxorubicin and cytarabine against AML cells. This
may be important since both conventional agents rep-
resent the backbone of AML treatment. Our studies on
the mechanism of action of bortezomib indicate that
this compound affects several pathways involved in the
control of cell cycle progression and apoptosis. In HEL
cells, bortezomib caused a progressive accumulation of
cells in G2/M with a decrease in the percentages of cells
in G0/G1 and S phases. Induction of G2/M arrest has pre-
viously been shown to occur in multiple myeloma,56
non-small cell lung cancer,10,11 and ovarian cancer17 cells
treated with bortezomib. Western blotting analyses
indicated changes in the amounts of pRb, p27 and
cyclin E. Furthermore, increased p27 levels have been
reported in multiple myeloma cells6 as well as in ovari-
an cancer cells17 following treatment with bortezomib. 
In addition to its effect on the cell cycle, bortezomib
provoked cell death, as shown by annexin V positivity,
loss of mitochondrial membrane potential, and DNA
fragmentation. Analyses of the effect of bortezomib on
AML cells indicated that this compound caused cleav-
age of the initiator caspases -8 and -9, effector caspase-
3; and PARP. The cleavage of caspase-3 and PARP is
consistent with results obtained in other types of tumor
cells6,10,11,17 treated with comparable exposure to borte-
zomib. Moreover, pretreatment with Z-VAD-FMK
blocked bortezomib-induced cell death suggesting that
the caspase-dependent apoptotic pathway is the main
executor of cell death caused by this compound. In line
with our observations, Hideshima et al.4 also showed
that caspase inhibitors were able to prevent borte-
zomib-induced apoptosis in multiple myeloma cells. 
The progressive loss of mitochondrial membrane
potential reflected an increase in the permeability of
the outer mitochondrial membrane, which allowed
release of pro-apoptotic proteins, such as AIF. The
release of AIF is facilitated by decreased levels of Bcl-2
family members, which have been shown to regulate
mitochondrial outer membrane permeability.43,57
Western blot analyses indicated that bortezomib
caused translocation of AIF from the mitochondrial to
cytosolic fraction and down-regulated the antiapoptot-
ic Bcl-2 family member Bcl-X. To the best of our
knowledge, the contribution of AIF to bortezomib-
induced cell death has not been previously reported. As
AIF has been involved in caspase-independent cell
death, our data both suggest a dual apoptotic mecha-
nism induced by bortezomib in AML cells, involving
both caspase-dependent and -independent pathways. 
Finally, we had the opportunity to analyze the effect
of bortezomib (compared to doxorubicin) on fresh cells
obtained from a cohort of AML patients. As mentioned
in the Design and Methods section, by using an appropri-
ate triple antigen combination plus simultaneous stain-
ing with annexin V we were able to separate the blast
cell population from the residual normal hematopoietic
cells and to assess the proportion of apoptotic cells
induced by the drug in each cell population. Moreover,
even in cases with co-existence of CD34+ and CD34–
blast cells, our immunophenotypic approach clearly
discriminated these two blast cell populations and
enabled subsequent measurement of apoptosis induced
in each subset. For this study, we used doxorubicin as a
reference drug since it is a cornerstone of the treatment
of AML. As observed in the cell lines, bortezomib
showed greater antitumor activity than doxorubicin on
patients’ fresh blast cells, although the difference did
not reach statistical significance. Interestingly, howev-
er, differences emerged when the CD34+ and CD34–
blast cell subsets were analyzed separately. Thus, while
bortezomib had a similar pro-apoptotic effect on both
cell populations, doxorubicin showed greater activity
on the more mature cells (CD34–). Moreover, borte-
zomib was significantly more active than doxorubicin
on immature CD34+ blast cells. This finding supports
the belief that bortezomib could overcome the drug
resistance associated with the immature phenotype.34
Moreover, since the cell subset most commonly respon-
sible for relapses is the CD34+ subset, bortezomib may
represent an ideal drug for the eradication of minimal
residual disease, which is currently the major therapeu-
tic challenge in the treatment of AML. Finally, we
observed that the antileukemic effect of bortezomib
was selective, since the toxicity to normal residual lym-
phocytes was low. Similarly, proteasome inhibition
specifically provoked apoptosis in CD34+/CD38–/
CD123+ cells (leukemic stem cells) without significant
toxicity to normal hematopoietic stem cells.58,59
In summary our study indicates that bortezomib has
marked in vitro activity in both AML cell lines and fresh
blast cells obtained from patients. Moreover, the simi-
lar antileukemic effect of bortezomib on CD34+ and
CD34– AML cells suggests that this agent may over-
come the drug resistance associated with the immature
CD34+ phenotype. Collectively, these data open new
pathways for the clinical development of bortezomib
in the treatment of AML, and may add this already
Bortezomib in acute myeloid leukemia
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approved drug to the therapeutic armamentarium
against AML. For more than 30 years very few novel
agents have been introduced to treat AML,60 and yet
many patients continue to relapse due to the persist-
ence of residual resistant leukemic cells. Our data clear-
ly support that further clinical investigation of borte-
zomib, particularly in combination with conventional
agents, is warranted.
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